CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals today announced positive results from the Company’s registration trial in cutaneous T-cell lymphoma (CTCL) and from a Phase 2 trial in CTCL and peripheral T-cell lymphoma (PTCL) conducted by the National Cancer Institute (NCI) at the 50th American Society of Hematology (ASH) Annual Meeting in San Francisco, CA. Romidepsin is a novel, cyclic peptide, histone deacetylase inhibitor under investigation for hematologic malignancies. Additionally, positive data emerging from a clinical trial of romidepsin in combination with Velcade® (bortezomib) and dexamethasone in multiple myeloma will be presented later at the meeting.
